Nimodipine

Overview

Nimodipine is a calcium channel blocker primarily used to reduce brain damage caused by a lack of oxygen brought on by bleeding from a burst blood vessel. It works by relaxing narrowed blood vessels in the brain, facilitating improved blood flow.

API suppliers (6)

Suppliers of Nimodipine evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• LUSOCHIMICA SPAItaly1 active DMF GMP on record
• DASAMI LAB PRIVATE LTDIndia1 active DMF GMP on record
• BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
• Laksh Fine Chem Private LimitedIndia1 active DMF
• Bayer Healthcare Llc GMP on record
• USV LTD GMP on record

EU CEP holders (3)

Companies holding a valid EU Certificate of Suitability (CEP) for Nimodipine, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (6 approved US products), the latest listed US patent on Nimodipine expires 16 Apr 2038. Generic API sourcing typically opens up once these lapse.

Therapeutic areas